New Study Reveals How Epigenetic Changes Can Impact Health and Disease

https://www.marketsandmarkets.com/Market-Reports/epigenetics-technologies-market-896.html

The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period. Significant reduction in the sequencing associated costs is among the key driving factors of the epigenetics market. Advent of affordable NGS systems along with the decline in cost of genome sequencing services boosts the epigenetics sequencing, further driving the market growth. Illumina, Inc. (US) has introduced various affordable NGS solutions over the years, post the launch of its iSeq benchtop sequencer in 2018. Additionally, declining costs have also rendered targeted bisulphite sequencing a feasible option, in turn driving the market growth.

Epigenetics market is moderately consolidated and competitive in nature, market players are adopting different strategies to sustain market competition. Prominent players have introduced cutting-edge solutions for epigenetic sequencing and epigenetic analysis to sustain the industry competition. Most prominent players have built a diverse portfolio of kits, reagents, and consumables to cater to customer needs. Prominent players in the global epigenetics market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories (US), Promega Corporation (US), PerkinElmer (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode (Germany), and F. Hoffmann-La Roche Ltd (Switzerland).